

LA JOLLA PHARMACEUTICAL CO

Form 8-K

July 24, 2003

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): July 24, 2003

**La Jolla Pharmaceutical Company**

---

(Exact Name of Registrant as Specified in Charter)

Delaware

---

0-24274

---

33-0361285

---

(State or Other Jurisdiction  
of Incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

6455 Nancy Ridge Drive, San Diego, California

---

92121

---

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

(858) 452-6600

---

N/A

---

(Former Name or Former Address, if Changed Since Last Report)

---

---

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On July 24, 2003, the Company issued a press release announcing that, based on recent discussions with the United States Food and Drug Administration (FDA), the Company may pursue an accelerated approval for its lupus drug candidate, Riquent , under the FDA's Subpart H regulation. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) *Exhibits.* The following exhibits are filed with this report on Form 8-K:

| <b>Exhibit<br/>Number</b> | <b>Description of Exhibit</b> |
|---------------------------|-------------------------------|
| 99.1                      | Press Release                 |

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LA JOLLA PHARMACEUTICAL COMPANY**

Date: July 24, 2003

By: /s/ Steven B. Engle

---

Steven B. Engle  
Chairman and Chief Executive Officer

---

**Table of Contents**

**EXHIBIT INDEX**

| <b>Exhibit<br/>Number</b> | <b>Description of Exhibit</b> |
|---------------------------|-------------------------------|
| 99.1                      | Press Release                 |